Raymond James Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with an Outperform rating and a price target of $24.
September 28, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has initiated coverage on Dianthus Therapeutics with an Outperform rating and a price target of $24, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. An Outperform rating suggests that the analyst expects the stock to do better than the market average. Additionally, a price target of $24 indicates the analyst's confidence in the stock's potential to reach this price, which could encourage investors to buy, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100